Delix Therapeutics, a clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens, announced the closing of an oversubscribed $100 million Series C financing. The round was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation JJDC, Inc., and SV Health Investors' Dementia Discovery Fund (DDF), with participation from existing investors, such as RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, as well as the addition of several new investors including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures among others.